- Page 1
- Page 2 - Page 3 - Page 4 - Page 5 - Page 6 - Page 7 - Page 8 - Page 9 - Page 10 - Page 11 - Page 12 - Page 13 - Page 14 - Page 15 - Page 16 - Page 17 - Page 18 - Page 19 - Page 20 - Page 21 - Page 22 - Page 23 - Page 24 - Page 25 - Page 26 - Page 27 - Page 28 - Page 29 - Page 30 - Page 31 - Page 32 - Page 33 - Page 34 - Page 35 - Page 36 - Page 37 - Page 38 - Page 39 - Page 40 - Page 41 - Page 42 - Page 43 - Page 44 - Page 45 - Page 46 - Page 47 - Page 48 - Page 49 - Page 50 - Page 51 - Page 52 - Page 53 - Page 54 - Page 55 - Page 56 - Page 57 - Page 58 - Page 59 - Page 60 - Page 61 - Page 62 - Page 63 - Page 64 - Page 65 - Page 66 - Page 67 - Page 68 - Flash version © UniFlip.com |
JOHN EMERSON
Dr. Mehnert is a principal investigator on studies that involve both classes of therapies and explore ways to increase the efficacy of these treatments in fighting melanoma. “We’re still a long way from a cure, but it’s been tremendously exciting to offer new therapies— and hope, where there was little before,” she says. Dr. Mehnert enthusiastically wel-
comes the new partnership between Rutgers and Robert Wood Johnson Medical School. The commitment of Rutgers Cancer Institute of New Jersey to the pursuit of clinical trials was critically important to her when she and her husband, Peter Vaclavik, MD ’02, considered where to practice and raise their three children. “I am a graduate of both institutions, and I am proud to
be able to bring the latest science to my home community,” she says. “The strides we make in this field are due to clinical research. It’s important for patients to be able to have access to cutting-edge treatments and trials. I’m thrilled to help make that happen for the world in general, but it’s even sweeter to be able to deliver this close to home.” M
Robert Wood Johnson I MEDICINE 61
|